Healing of intestinal inflammation by IL-22

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1777-1784

  Mizoguchi, Atsushi ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b 149 CNY 6024 ^*  (United States)

Author keywords

antibacterial proteins; epithelial defense; epithelial regeneration; inflammatory bowel disease; mucin 1; susceptibility genes

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; AROMATIC HYDROCARBON RECEPTOR; FICZ; INTERLEUKIN 22; STAT3 PROTEIN; UNCLASSIFIED DRUG;

CELL REGENERATION; CHRONIC DISEASE; CROHN DISEASE; DRUG TARGETING; EPITHELIUM CELL; GENETIC SUSCEPTIBILITY; GOBLET CELL; HUMAN; INNATE IMMUNITY; INTESTINE INJURY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; WOUND HEALING;

ANIMALS; HUMANS; INFLAMMATION; INTERLEUKINS; INTESTINES;

EID: 84864966419     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22929     Document Type: Review

References (95)

1. Dumoutier L, Louahed J, Renauld JC,. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000; 164: 1814-1819.
2. Seiderer J, Brand S,. IL-22: a two-headed cytokine in IBD? Inflamm Bowel Dis. 2009; 15: 473-474.
3. Witte E, Witte K, Warszawska K, et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010; 21: 365-379.
4. Zenewicz LA, Flavell RA,. Recent advances in IL-22 biology. Int Immunol. 2011; 23: 159-163.
5. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29: 71-109.
6. Sonnenberg GF, Fouser LA, Artis D,. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011; 12: 383-390.
7. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004; 21: 241-254.
8. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005; 129: 969-984.
9. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008; 118: 534-544.
10. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008; 29: 947-957.
11. Sanos SL, Bui VL, Mortha A, et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol. 2009; 10: 83-91.
12. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009; 457: 722-725.
13. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007; 27: 647-659.
14. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007; 445: 648-651.
15. Ma HL, Liang S, Li J, Napierata L, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008; 118: 597-607.
16. Laurence A, O'Shea JJ, Watford WT,. Interleukin-22: a sheep in wolf's clothing. Nat Med. 2008; 14: 247-249.
17. Mizoguchi A, Mizoguchi E,. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol. 2010; 10: 578-587.
18. Lee JS, Cella M, McDonald KG, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol. 2011; 13: 144-151.
19. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G827-838.
20. Sekikawa A, Fukui H, Suzuki K, et al. Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab Invest. 2010; 90: 496-505.
21. Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. 2009; 206: 1465-1472.
22. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008; 14: 204-212.
23. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
24. Mizoguchi A,. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci. 2012; 105: 263-320.
25. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008; 181: 7420-7427.
26. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009; 10: 857-863.
27. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009; 10: 864-871.
28. Simonian PL, Wehrmann F, Roark CL, et al. ÎÎ́ T cells protect against lung fibrosis via IL-22. J Exp Med. 2010; 207: 2239-2253.
29. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008; 14: 275-281.
30. Hughes T, Becknell B, Freud AG, et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010; 32: 803-814.
31. Male V, Hughes T, McClory S, et al. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol. 2010; 185: 3913-3918.
32. Spits H, Di Santo JP,. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol. 2011; 12: 21-27.
33. Vivier E, Spits H, Cupedo T,. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol. 2009; 9: 229-234.
34. Sawa S, Cherrier M, Lochner M, et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science. 2010; 330: 665-669.
35. Muñoz M, Heimesaat MM, Danker K, et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med. 2009; 206: 3047-3059.
36. Pariente B, Mocan I, Camus M, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology. 2011; 141: 217-226.
37. Takayama T, Kamada N, Chinen H, et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010; 139: 882-892.
38. Geremia A, Arancibia-Cárcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011; 208: 1127-1133.
39. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008; 14: 282-289.
40. Tumanov AV, Koroleva EP, Guo X, et al. Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe. 2011; 10: 44-53.
41. Sonnenberg GF, Monticelli LA, Elloso MM, et al. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity. 2011; 34: 122-134.
42. Rutz S, Noubade R, Eidenschenk C, et al. Transcription factor c-Maf mediates the TGF-β-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol. 2011; 12: 1238-1245.
43. Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009; 206: 35-41.
44. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008; 453: 106-109.
45. Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011; 141: 237-248.
46. Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012; 36: 92-104.
47. Pestka S, Krause CD, Sarkar D, et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004; 22: 929-979.
48. Nagalakshmi ML, Rascle A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol. 2004; 4: 679-691.
49. Wolk K, Witte E, Hoffmann U, et al. IL-22 induces lipopolysaccharide- binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol. 2007; 178: 5973-5981.
50. Dumoutier L, de Meester C, Tavernier J, et al. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem. 2009; 284: 26377-26384.
51. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 1544-1555.
52. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 36: 1309-1323.
53. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006; 203: 2271-2279.
54. Mizoguchi E, Xavier RJ, Reinecker HC, et al. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology. 2003; 125: 148-161.
55. Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006; 313: 1126-1130.
56. Brandl K, Plitas G, Schnabl B, et al. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007; 204: 1891-1900.
57. Cox JH, Kljavin NM, Ota N, et al. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol. 2012; 5: 99-109.
58. Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011; 12: 1151-1158.
59. Hattrup CL, Gendler SJ,. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008; 70: 431-457.
60. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008; 455: 808-812.
61. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485-498.
62. Nishida A, Lau CW, Zhang M, et al. The membrane-bound mucin Muc1 regulates Th17-cell responses and colitis in mice. Gastroenterology. 2011 [Epub ahead of print].
63. Kadayakkara DK, Beatty PL, Turner MS, et al. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas. 2010; 39: 510-515.
64. Beatty PL, Plevy SE, Sepulveda AR, et al. Transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol. 2007; 179: 735-739.
65. An G, Wei B, Xia B, McDaniel JM, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 2007; 204: 1417-1429.
66. Stone EL, Ismail MN, Lee SH, et al. Glycosyltransferase function in core 2-type protein O glycosylation. Mol Cell Biol. 2009; 29: 3770-3782.
67. Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009; 183: 687-695.
68. Yuan ZL, Guan YJ, Wang L, et al. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol. 2004; 24: 9390-9400.
69. Neufert C, Pickert G, Zheng Y, et al. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle. 2010; 9: 652-655.
70. Fukui H, Sekikawa A, Tanaka H, et al. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowel Dis. 2011; 17: 1177-1188.
71. Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010; 52: 1291-1300.
72. Kapessidou P, Poulin L, Dumoutier L, et al. Interleukin-22 deficiency accelerates the rejection of full major histocompatibility complex-disparate heart allografts. Transplant Proc. 2008; 40: 1593-1597.
73. Chang H, Hanawa H, Liu H, et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol. 2006; 177: 3635-3643.
74. Nakagome K, Imamura M, Kawahata K, et al. High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism. J Immunol. 2011; 187: 5077-5089.
75. Ke Y, Sun D, Jiang G, et al. IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol. 2011; 187: 2130-2139.
76. Geboes L, Dumoutier L, Kelchtermans H, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009; 60: 390-395.
77. Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011; 186: 1228-1239.
78. Kreymborg K, Etzensperger R, Dumoutier L, et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol. 2007; 179: 8098-8104.
79. Dhiman R, Indramohan M, Barnes PF, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol. 2009; 183: 6639-6645.
80. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest. 2010; 120: 1762-1773.
81. Schulz SM, Köhler G, Schütze N, et al. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol. 2008; 181: 7891-7901.
82. De Luca A, Zelante T, D'Angelo C, et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 2010; 3: 361-373.
83. Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009; 136: 257-267.
84. Kamanaka M, Huber S, Zenewicz LA, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011; 208: 1027-1040.
85. Shimomura Y, Ogawa A, Kawada M, et al. A unique B-2 B cell subset in the intestine. J Exp Med. 2008; 205: 1357-1368.
86. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med. 2009; 87: 523-536.
87. Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med. 2010; 207: 1293-1305.
88. Xu W, Presnell SR, Parrish-Novak J, et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A. 2001; 98: 9511-9516.
89. Dumoutier L, Lejeune D, Colau D, et al. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol. 2001; 166: 7090-7095.
90. Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol. 2001; 166: 7096-7103.
91. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
92. Khor B, Gardet A, Xavier RJ,. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317.
93. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033-2045.
94. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009; 41: 216-220.
95. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 1118-1125.